A Global Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With EBV-Positive (EBV+) Relapsed/Refractory Peripheral T Cell Lymphomas (NAVAL-1)

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

nanatinostat (VRx-3996) - Viracta Therap

https://clml-soho2024.elsevierdigitaledition.com/II/index.html

Ranjit Nair Clinical Medical Director, MD 1; Hung Chang MD 2; Irl Brian Greenwell MD, Associate Professor 3; Hui-Hua Hsiao MD, PhD 4; Swaminathan Ayer MD 1; Luigi Zinzani MD, Professor 5; Donald Strickland MD 6; Eva González-Barca MD 7

Aug 31, 2024